PhoreMost Ltd, a 2015 spin-out from Cambridge University with technology for identifying new drug targets, has appointed Lorenz Mayr to its board as a non-executive director. Dr Mayr is chief technology officer at GE Healthcare Life Sciences where he is responsible for R&D strategy across all life science business areas. He previously held executive positions in R&D at AstraZeneca Plc, Novartis Pharmaceuticals and Bayer Pharmaceuticals.
Dr Mayr gained his PhD in biochemistry and biophysics at the University of Bayreuth, Germany and completed postdoctoral research at the MIT/Whitehead Institute in Cambridge, US.
PhoreMost announced the appointment on 15 July 2019.
Copyright 2019 Evernow Publishing Ltd.